Table 2.

Pooled risk ratios of lung cancer in individuals exposed to ACEIs stratified by subgroups.

Subgroups	RR (95% CI)	Q (P -value)	Number of studies	Heterogeneity I2 (P -value)
Study design		0.65 (.72)
Case-Control	1.06 (0.82–1.37)		4	(0).44
Cohort	0.94 (0.81–1.10)		8	(85.8%) <.001
RCT	1.01 (0.65–1.56)		1	(0) 1.00
Comparator regimen		3.37 (.19)
ARB	1.11 (0.89–1.39)		4	(0) .60
BB/CCB/D	0.82 (0.64–1.05)		6	(88.9%) <.001
Controls	0.91 (0.66–1.25)		3	(36.9) .21
Duration of ACEI use		0.05 (.83)
≤5 years	0.95 (0.75–1.20)		9	(76.7%) .001
>5 – 10 years	0.98 (0.83–1.15)		4	(82.3%) .001